<DOC>
	<DOCNO>NCT02521545</DOCNO>
	<brief_summary>The primary objective study assess pharmacokinetic ( PK ) profile BIIB061 new oral formulation fast state healthy male female volunteer . The secondary objective study evaluate safety tolerability BIIB061 new formulation study population .</brief_summary>
	<brief_title>Single-Dose Study New Formulation BIIB061</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Key Males postmenopausal ( defined menses 12 month confirm folliclestimulating hormone [ FSH ] level determine screen postmenopausal range ) surgically sterile female . All male subject must practice effective contraception study willing able continue male contraception 3 month dose study treatment . All male subject must also willing refrain sperm donation least 3 month dose study treatment . Must good health normal vital sign determine Investigator , base medical history screening evaluation . Body mass index 18.0 30.0 kg/m2 , inclusive . Key History positive test result screen human immunodeficiency virus , hepatitis C virus antibody , hepatitis B virus ( define positive hepatitis B surface antigen [ HBsAg ] hepatitis B core antibody [ HBcAb ] ) . Prior exposure BIIB061 . History clinically significant cardiac , endrocrinologic , hematologic , hepatic , gastric , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , oncologic , major disease , determine Investigator . Treatment prescription medication within 28 day prior throughout duration study . Use overthecounter product , include herbal alternative health preparation within 14 day prior study Enrollment interventional clinical study investigational drug , biologic , device , approve therapy investigational use administer use within 30 day prior study Any live attenuate immunization/vaccination give within 30 day prior study plan give study . Blood donation within 30 day prior study Surgery within 3 month prior study NOTE : Other protocol define Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Oral Remyelination</keyword>
</DOC>